Delving into the Latest Updates on Aerogen Pharma Limited with Synapse

A South African, multicenter, phase 2, non-blinded, randomized controlled trial to determine if aerosolized surfactant plus continuous positive airway pressure (CPAP) compared to CPAP alone can improve the course of infants with respiratory distress syndrome (RDS) by decreasing their need for intratracheal bolus surfactant in the first 72 hours of age

开始日期2023-05-14

申办/合作机构

Aerogen Pharma Limited

NCT04452669 / Completed临床2期

Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of VentaProst (Inhaled Epoprostenol Delivered Via Dedicated Delivery System) in Subjects With COVID-19 Requiring Mechanical Ventilation

The purpose of this study is to investigate whether inhaled epoprostenol given via a breath actuated delivery system will help improve oxygen levels and treatment outcomes in patients with COVID-19 who are on mechanical ventilation.

开始日期2020-09-15

申办/合作机构

Aerogen Pharma Limited

[+1]

NCT03969992 / Completed临床2期

A Partially Blinded, Randomized, Controlled, Parallel-Group, Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact in Preterm Infants at Risk of Worsening Respiratory Distress Syndrome

The purpose of this two-part Phase 2 study is to assess the safety, tolerability and efficacy of aerosolized SF-RI 1 (AeroFact) when delivered via nCPAP at two different doses.

开始日期2020-03-04

申办/合作机构

Aerogen Pharma Limited

100 项与 Aerogen Pharma Limited 相关的临床结果

登录后查看更多信息

0 项与 Aerogen Pharma Limited 相关的专利（医药）

登录后查看更多信息

100 项与 Aerogen Pharma Limited 相关的药物交易

登录后查看更多信息

100 项与 Aerogen Pharma Limited 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月04日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床2期

1

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Bovactant(Boehringer Ingelheim GmbH)	新生儿呼吸窘迫综合征更多	临床2期
依前列醇钠 ( PGI2 receptor )	新型冠状病毒感染更多	无进展